Nymox Pharmaceutical (NYMXF) reports U.S. dismissal and Bahamas case withdrawal

Rhea-AI Filing Summary

Nymox Pharmaceutical Corporation reports favorable developments in two legal matters involving Randall Lanham and related parties. A U.S. District Court in the Central District of California granted the Company’s and Computershare Investor Services Inc.’s motion to dismiss Mr. Lanham’s complaint and dismissed the case with prejudice, meaning it cannot be refiled in that court. Separately, the Registrar for the Supreme Court of The Bahamas held a final hearing in a related case brought by Mr. Lanham, Mr. Riley, CRNSV, and others; that case was withdrawn, and the Registrar awarded costs to the Company. The specific cost details will be reported after the Bahamian Court issues its final Order, which the Company expects soon.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the Month of September, 2025

Commission File Number: 001-12033

Nymox Pharmaceutical Corporation

(Translation of registrant’s name into English)

Bay & Deveaux Streets, Nassau, The Bahamas

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

Nymox Pharmaceutical Corporation (the “Company”) reports that the U.S. District for the Central District of California granted the Company’s and Computershare Investor Services Inc.’s motion to dismiss Randall Lanham’s complaint, and dismissed the case, with prejudice.

The Company also reports that the Registrar for the Supreme Court of Bahamas held a final hearing in the case brought by Mr. Lanham, Mr. Riley, CRNSV, and others, which was withdrawn. The Registrar awarded costs to the Company, the details of which will be reported once the Bahama’s Court issues its final Order. The Company expects the final Order to be issued soon.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 22, 2025

	NYMOX PHARMACEUTfCAL CORPORATION
	By:
	Name:	Paul Averback
	Title:	President and Chief Executive Officer

3

FAQ

What legal update did Nymox Pharmaceutical (NYMXF) report in its September 6-K?

Nymox Pharmaceutical reported favorable outcomes in two legal cases involving Randall Lanham and related parties. A U.S. federal court dismissed Mr. Lanham’s complaint with prejudice, and a related case in The Bahamas was withdrawn, with the Registrar awarding costs to the Company.

What happened in the U.S. lawsuit against Nymox Pharmaceutical (NYMXF)?

The U.S. District Court for the Central District of California dismissed the complaint filed by Randall Lanham against Nymox and Computershare Investor Services Inc. The court granted their motion to dismiss and ended the case with prejudice, preventing refiling of that complaint in that court.

What is the status of the Bahamas case involving Nymox Pharmaceutical (NYMXF)?

The Bahamas case brought by Mr. Lanham, Mr. Riley, CRNSV, and others was withdrawn after a final hearing before the Registrar for the Supreme Court of The Bahamas. The Registrar awarded costs to Nymox, with detailed amounts to be disclosed after the final Order.

What did the Registrar in The Bahamas decide regarding costs for Nymox Pharmaceutical (NYMXF)?

The Registrar awarded costs to Nymox Pharmaceutical Corporation in the case that had been brought by Mr. Lanham, Mr. Riley, CRNSV, and others. Nymox stated it will report the details once the Supreme Court of The Bahamas issues its final Order.

Who signed Nymox Pharmaceutical’s (NYMXF) September 2025 6-K filing?

The 6-K was signed on behalf of Nymox by Paul Averback, who is identified as the Company’s President and Chief Executive Officer. His signature confirms the Company’s authorization of the report submitted under the Securities Exchange Act of 1934.

What does "dismissed with prejudice" mean for Nymox Pharmaceutical’s U.S. case?

"Dismissed with prejudice" means the U.S. case is permanently closed as filed, and the same complaint cannot be brought again in that court. For Nymox, it indicates the federal lawsuit by Randall Lanham has been definitively concluded there.